Most multivalent inhibitors are designed to target Gal-3, such as the polysaccharides GM-CT-01 (Davanat) and GR-MD-02 (Belapectin) developed by Galectin Therapeutics, which have been patented as cancer treatments [386–389]. This evidence concerns the gene LGALS3 and cancer.